Amisulpride has no effect on plasma clozapine concentrations.

  title={Amisulpride has no effect on plasma clozapine concentrations.},
  author={Niels Bergemann and Kai R Kress and Alex Frick and J{\"u}rgen Kopitz},
  journal={Journal of clinical psychopharmacology},
  volume={25 5},
To the Editors: To date, only a few systematic studies analyzing the use of combinations of antipsychotics have been undertaken. However, knowing how clozapine and amisulpride interact could be particularly important as patients with schizophrenia might well profit from such a combination treatment; indeed, a few case reports and studies support this notion. Good efficacy and tolerability of this combination in treating positive and negative symptoms have been reported even when the disease has… 
Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation
  • A. Kreinin, C. Miodownik, V. Lerner
  • Psychology, Medicine
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2011
Although moclobemide exceeded amisulpride in antisalivation activity, treatment of CIS with amisULpride leads to improvement in psychotic symptoms, and both medications were safe and effective as treatment of CAS.
High-dose ziprasidone in treatment-resistant schizophrenia and affective spectrum disorders: a case series.
A retrospective electronic record review of 106 evaluable records of patients with schizophrenia and affective spectrum disorders treated with higher doses of ziprasidone in inpatient, partial hospital, and outpatient settings at a community general hospital in the southwest suburbs of Cleveland, OH found large improvement in symptom severity and effects on the QTc interval were found.
Drug interactions affecting clozapine levels
Clinicians must maintain increased clinical vigilance for adverse side effects when clozapine is combined with other medications and the role of routine clozAPine monitoring in clinical practice requires further clarification.
Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder
Neither the age-dependent decrease of amisulpride clearance nor the significantly higher prevalence of co-morbidity and co-medication seem to be the reasons for definite clinical concerns against amisULpride treatment of elderly if contraindications are seriously taken.
Current awareness: Pharmacoepidemiology and drug safety
  • Medicine
    Pharmacoepidemiology and drug safety
  • 2008
The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety in order to keep subscribers up‐to‐date with the latest developments in their field.
Pregabalin-associated increase of clozapine serum levels.


Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.
The combination of amisulpride with clozapine considerably enriches the therapeutic arsenal in cases of severe schizophrenic psychoses and reduces the side effects of monotherapy.
Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
Amisulpride is characterized as a specific dopamine receptor antagonist with high and similar affinity for the dopamine D2 and D3 receptor with a degree of limbic selectivity and a preferential effect, at low doses, on dopamine D 2/D3 autoreceptors.
A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers
Studies in humans have shown that amisulpride is free of behavioural toxicity at doses exerting clear antipsychotic efficacy and confirm that its CNS effects may vary with the dose administered, and is clearly better than that of haloperidol 4 mg/day.
Sulpiride augmentation in people with schizophrenia partially responsive to clozapine
A subgroup of patients with chronic schizophrenia may substantially benefit from sulpiride addition to clozapine, and exhibited substantially greater and significant improvements in positive and negative psychotic symptoms.
Omeprazole reduces clozapine plasma concentrations. A case report.
The co-medication with omeprazole was associated with a reduction in the plasma levels of clozapine of 41.9 % and 44.7 %, respectively, in these patients, which might be due to the induction of the cytochrome P450 isoenzyme CYP1A2.
Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy.
Preliminary reports support the use of add-on topiramate in adults with generalised epilepsy, in childhood epilepsies and in patients with Lennox-Gastaut syndrome, as well as theUse of topIRamate monotherapy in patientsWith refractory epilepsy,topiramate can be considered an important new drug for the management of patients with refractors.
Differential effects of long-term treatment with clozapine or haloperidol on GABA transporter expression.
It is concluded that long-term antipsychotic treatment alters GABA transporter expression in rat, and the upregulation of GAT-1 contrasts with the post-mortem finding of reduced Gat-1 expression in schizophrenic patients.
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
Olanzapine seemed to have a risk-versus-benefit advantage in the management of psychotic symptoms, and the differential preclinical profiles of these two drugs were also evident in a controlled, clinical investigation.
Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia.
Because of the demonstration of a selective alpha nicotinic receptor abnormality in patients with schizophrenia, galantamine was added to the stable regimen of atypical and other antipsychotic